SAE (Serious Adverse Event)

SAE (Serious Adverse Event) - Axcellant

SAE (Serious Adverse Event)

  1. lut 28, 2025

What Does the 'SAE (Serious Adverse Event)’ Mean?

SAE stands for Serious Adverse Event in clinical research. It refers to any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, or results in persistent or significant disability/incapacity.

SAEs are a crucial aspect of drug safety monitoring during clinical trials. They must be promptly reported to regulatory authorities and ethics committees, and may lead to changes in study protocols or even the termination of a clinical trial if the risk to participants is deemed too high.

Why Is the 'SAE (Serious Adverse Event)’ Important in Clinical Research?

SAEs are critical indicators of a drug’s safety profile during clinical trials. They help researchers and regulatory bodies assess the potential risks associated with investigational treatments, ensuring that participant safety remains the top priority throughout the study.

The identification and proper reporting of SAEs can significantly impact the course of a clinical trial and the eventual approval of a new drug. Timely recognition and management of SAEs allow for appropriate interventions, protocol modifications, and informed decision-making regarding the continuation or termination of a study.

Good Practices and Procedures

  1. Establish a clear SAE assessment and grading system aligned with regulatory guidelines to ensure consistent evaluation across all study sites.
  2. Implement a 24/7 SAE reporting hotline for immediate notification and guidance to investigators and site staff.
  3. Conduct regular SAE recognition and management training for all clinical trial personnel, including refresher courses throughout the study duration.
  4. Develop a comprehensive SAE follow-up protocol to track patient outcomes and gather additional data for thorough causality assessment.
  5. Perform periodic SAE trend analyses to identify potential safety signals and proactively adjust risk mitigation strategies.

Related Terms

Read more

Axcellant partners with Prometheus MedTech.AI to accelerate AI-powered cardiac diagnostics

We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…

Axcellant at EANM 2025: What We Brought Back from Barcelona

The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…

Radioisotopes in Medicine: Clinical Applications, Safety, and Regulatory Considerations

The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…